Related Experiment Video
Updated: Apr 27, 2026
17:28
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
10.8K
Novel biomarker platforms in toxicology
1Biotrin International, 93 The Rise, Mount Merrion, Co Dublin, Ireland.
Drug Discovery Today. Technologies
|July 2, 2014
Summary
Drug development is costly, with many compounds failing due to toxicity. Novel biomarkers can improve decision-making, reducing costs and post-launch withdrawals.
Area of Science:
- Pharmacology
- Biomarker Discovery
- Drug Development
Background:
- High attrition rates in drug development lead to significant financial losses.
- Post-launch drug withdrawals due to toxicity remain a persistent issue despite extensive testing.
- Novel biomarkers offer a potential solution to improve early-stage decision-making.
Purpose of the Study:
- To review the value of novel biomarkers in drug development.
- To identify barriers hindering the introduction of new biomarkers.
- To assess the impact of biomarkers on reducing drug development costs and toxicity issues.
Main Methods:
- Literature review of existing biomarkers in drug development.
- Analysis of case studies on biomarker implementation.
- Discussion of regulatory and technical challenges for biomarker adoption.
Main Results:
- Biomarkers can enhance the prediction of compound efficacy and toxicity.
- Successful biomarker implementation can lead to more informed go/no-go decisions.
- Significant barriers include validation, standardization, and integration into clinical practice.
Conclusions:
- Novel biomarkers are crucial for optimizing drug development pipelines.
- Overcoming implementation barriers is essential to realize the full potential of biomarkers.
- Biomarkers promise to reduce costs and improve patient safety by minimizing toxic drug failures.
